[1] BENJAMIN E J, MUNTNER P, ALONSO A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association[J]. Circulation,2019,139(10): e56-e528.
[2] AGENO W, GALLU A S, WITTKOWSKY A, et al. Oral anticoagulant therapy: Anti- thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl):e44S-e88S.
[3] LIPPI G, CERVELLIN G, FRANCHINI M,et al. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future[J]. J Thromb Thrombolysis, 2010, 30(4): 459-471.
[4] SADANAGA T, SADANAGA M, OGAWA S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy[J]. J Am Coll Cardiol, 2010, 55(20): 2225-2231.
[5] BOUGET J, HUET M C, Roy P M, et al. Acute, major muscular hematoma associated with antithrombotic agents: a multicenter real-world cohort[J]. Thromb Res, 2021, 199: 54-58.
[6] WITT D M, DELATE T, HYLEK E M, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes[J]. Thromb Res, 2013, 132(6):770-775.
[7] GARCIA RODRIGUEZ L A, LIN K J, HERNANDEZ-DIAZ S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications[J]. Circulation, 2011, 123(10):1108-1115.
[8] BOUGET J, BALUSSON F, SCAILTEUX L M, et al. Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide health insurance database linked to emergency department records within five areas - rationale and design of SACHA study[J]. Fundam Clin Pharmacol, 2019, 33(4): 443-462.
[9] BOUGET J, BALUSSO F N, MAIGNAN M, et al. Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study[J], Br J Clin Pharmacol, 2020, 86(12): 2519-2529.
[10] HINDRICKS G, POTPARA T, DAGRES N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2021, 42(5): 373-498.
[11] JANUARY C T, WANN L S, CALKINS H,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation, 2019, 140(2): e125-e151.
[12] 吴怡婷, 邢云利, 孙颖. 衰弱对于老年心房颤动患者抗凝决策的影响[J]. 中华老年多器官疾病杂志, 2020, 19(12): 945-948.
[13] 艾阳, 李必龙, 朱春甲, 等. 低剂量利伐沙班在老年非瓣膜性房颤治疗中的效果观察[J]. 实用老年医学, 2020, 34(7): 666-669.
[14] 柯森淼, 林炳基, 贺友生. 利伐沙班防治老年髋部骨折后下肢深静脉血栓的临床效果观察[J]. 临床合理用药杂志, 2020, 13(32): 75-76.
[15] ALMORAD A, OHANYAN A, PINTEA BENTEA G, et al. D-dimer blood concentrations to exclude left atrial thrombus in patients with atrial fibrillation[J]. Heart, 2021, 107(3): 195-200. |
